The IL-23 receptor-targeted oral peptide psoriasis drug, Icotinib tablets, has been included in the drug price list in Japan.
On November 13, 2026, the oral peptide psoriasis treatment drug, Icotinib tablets targeting the IL-23 receptor, was included in the Japanese drug pricing list. This is the world's first orally administrable IL-23 receptor-targeting drug, and is expected to expand the options for psoriasis treatment.
Why it matters. New treatment options are provided for psoriasis patients, and in particular, the introduction of orally administrable drugs is considered to contribute to the improvement of patients' quality of life.